May 5 (Reuters) – Cytokinetics said on Tuesday its experimental heart disease drug significantly improved symptoms of a genetic heart condition in a late-stage trial.
Shares of the company were up 13.2% at $74.78 in premarket trading.
The company was testing the drug, chemically known as aficamten, in patients with a genetic heart condition called non-obstructive hypertrophic cardiomyopathy, where the heart muscle thickens without blocking blood flow.
The drug, under the brand name Myqorzo, was approved for patients with obstructive hypertrophic cardiomyopathy, a condition in which the heart muscle becomes abnormally thick and forms an obstruction that can reduce blood flow to the body.
(Reporting by Sneha S K; Editing by Devika Syamnath)
Brought to you by www.srnnews.com